At the 20th Congress of the European Hematology Association (EHA), Charles Craddock, FRCPath, FRCP, DPhil, BMBCh, of the University of Birmingham, Birmingham, UK, discusses the Trials Acceleration Programme (TAP) initiative by Leukaemia & Lymphoma Research. TAP aims to accelerate the clinical development of new therapies for patients with blood cancer through the creation of a network of leading treatment centers around the UK.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates